KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction.

Dylan M Buller, Maria Antony, Benjamin T Ristau

Onco Targets Ther 16 49-64

PMID36718243
PMCIDPMC9884052
DOI10.2147/OTT.S393296
发表日期2023-01-31
摘要

摘要

Locally and regionally advanced renal cell carcinoma (RCC) can recur at high rates even after visually complete resection of primary disease. Both targeted therapies and immunotherapies represent potential agents that might help reduce recurrence of RCC in these patients. This paper reviews the current body of evidence defining their potential impact and examines the large Phase III randomized clinical trials that have been performed to assess the safety and efficacy of these systemic therapies in the adjuvant setting. Given that the findings from these trials have been predominantly negative, this paper also explores the role of other potential adjuvant agents, including single and combination agent targeted therapies and immunotherapies, whose use is currently limited to metastatic RCC. Finally, the use of radiation therapy and the use of advanced imaging modalities in RCC are also considered.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。